Pfizer India

Anand Rathi is bullish on Pfizer India has recommended buy rating on the stock with a target price of Rs 4800 in its research report dated February 10, 2023.

Pfizer India, Max Hospitals join hands to promote research on drug efficacy

The research will focus on prevention, treatment and management of diseases that are of public health priority in India such as cancer and cardiovascular diseases

Hike in cash aid for patients with rare diseases raises hopes for entry of new ‘orphan drugs’ in India

The change has come through a modification in the National Policy for Rare Diseases, which was first notified in 2021

Buy Pfizer India; target of Rs 5655: Anand Rathi

Anand Rathi is bullish on Pfizer India has recommended buy rating on the stock with a target price of Rs 5655 in its research report dated February 08, 2021.

Experts discuss agenda for new govt beyond Budget 2014

An expert panel consisting Rashesh Shah, Chairman and CEO of the Edelweiss Financial Services Group, Kewal Handa, Former Managing Director of Pfizer India and Piruz Khambatta, Chairman Private limited discuss the agenda for the government beyond Budget 2014‘s hits and misses on ‘Change India‘s second episode.

More clarity needed on non-compete clause: Medybiz

The department of industrial policy and promotion (DIPP) today notified the new FDI policy for the pharma sector. The new policy retains old norms of keeping the FDI cap at 100 % for the sector.

Buy UltraTech, Madras Cements, Pfizer, Mcleod: AnandRathi

AnandRathi Securities has recommended to buy UltraTech Cement, Pfizer, Madras Cements and Mcleod Russel India with a target price of Rs 2100, Rs 215, Rs 1232 and Rs 400 respectively, in its research report dated July 30, 2013.

Budget 2012: Hardly a cure for pharma sector?

Budget 2012 saw the healthcare and pharmaceutical sector getting quite a few mentions. While these brought some booster shots for the industry, Players are not jumping for joy, reports CNBC-TV18’s Archana Shukla.

Union Budget 2012: Pharma pins hopes on FM

While dealing with fiscal challenges is likely to be the FM's core focus this Budget, the pharma industry, on its part, hopes that Pranab Mukherjee will also look into some of their long standing demands. CNBC-TV18’s Swathi Narayanan and Archana Shukla report on the pharma and healthcare sectors' wishlist for Budget 2012.

Govt's draft National Pharma Pricing Policy find few takers

The government's aim to regulate prices of all 348 essential drugs in the country is not going well with the Indian pharma industry.

CCI's role key in pharma FDI; FIPB not best option: Pfizer

The Arun Maira committee report on pharma FDI was accepted by the government which said the CCI should be entrusted with the task of scrutinising pharma FDI in brownfield projects. Kewal Handa, Country Manager at Pfizer India tells CNBC-TV18 feels it is just going back to the old regime of FIPB.